Mesothelin

Product List

Creative Biolabs provides various anti-Mesothelin-related products to support global customers’ projects, please feel free to contact us for further communication.

Background

Mesothelin encoded by MSLN, is a cell surface glycoprotein that is involved in kinds of important biological processes, such as cell proliferation, cell growth, cell adhesion, etc. Mesothelin overexpression is presented in several tumor types, including hematological malignancies, ovarian carcinomas, and lung adenocarcinomas. As the wide functions of mesothelin play, many researchers have been focused on the development of targeting mesothelin drugs, such as mesothelin antibodies, mesothelin ADC, and mesothelin CAR-T.

Fig.1 Schematic representation of Mesothelin-CART for associated diseases.¹

Associated Diseases

• Mesothelioma
• Ovarian cancer
• Pancreatic cancer
• Lung malignancy
• Breast cancer
• Gastric cancer
• Hematological malignancies

Anti-Mesothelin CAR-T Services

Anti-Mesothelin CAR-T In Vitro Assays

Anti-Mesothelin CAR-T Phenotype Characterization

CAR-T cell phenotype analysis provides a lot of intuitive and valuable information for development, including T cell subset distribution, CAR-T cell activity, and CAR-T cell exhaustion function. Creative Biolabs specializes in providing comprehensive phenotype characterization services for global customers to support CAR-T development.

Fig.2 Exhaustion phenotype analysis of TIM3, PD1, and LAG3 on anti-Mesothelin CART cells by flow cytometry. (Red is target antibody, green is isotype control).¹

Anti-Mesothelin CAR-T Expression Test

The evaluation of CAR expression is a key step in CAR-T development. The most common method is based on a flow cytometry approach with appropriate CAR detection reagents to assess. Creative Biolabs has successfully developed kinds of robust CAR expression reagents (target-specific reagents, linker-specific antibodies) for CAR-T cell analysis. Based on these sensitive reagents, we also provide comprehensive CAR expression testing services for global customers to accelerate the development of CAR-T.

Fig.3 CAR expression testing of anti-MSLN CART by flow cytometry. B). Flow analysis diagram of anti-MSLN CART proportion. C). Histogram of the MSLN-CAR positive subpopulation.¹

Anti-Mesothelin CAR-T Cytokine Release Test

The cytokine-releasing response occurs in the incubation process of CART cells and target tumor cells, and these cytokines reflect the strength of CART cells’ response to the corresponding target cell to some extent. Leveraging Creative Biolabs’ expertise in cytokine array to evaluate the production of various cytokine in CART cells, customers will receive reliable cytokine profiling analysis data to support subsequent development studies.

Fig.4 Cytokine releasing analysis of IFN-g and TNF-a in anti-MSLN CART cells co-cultured with different target cells 24 hrs.¹

Anti-Mesothelin CAR-T In Vitro Cytotoxicity Assay

The tumor-killing efficacy of CART is affected by its activation, expansion, and exhaustion processes. A robust and sensitive anti-tumor assay is a fundamental requirement for the translation of these CAR-T "living drugs". At Creative Biolabs, we offer various of CART in vitro cytotoxicity testing services, including chromium release-based assay, bioluminescence-based assay, flow cytometry-based assay, and RTCA assay.

Fig.5 Cytotoxicity evaluation of anti-MSLN CART cells against 3 solid tumor cell lines detected by RTCA assay. The red arrow indicated the time point at which effector cells are added.¹

Anti-Mesothelin CAR-T In Vivo Assays

Efficacy Test of Anti-Mesothelin CAR-T

For CART in vivo efficacy assessment, we provide a variety of animal models for customers to choose from, and we also provide optimized experimental design and efficacy evaluation tests to facilitate customers to get effective and reliable data most conveniently.

Efficacy Test of Anti-Mesothelin CAR-T in CDX Model

Fig.6 In vivo anti-tumor efficacy of anti-MSLN CART cells in HCT116 CDX model. B). The tumor size measurement of CDX model treated with anti-MSLN CART cells. C). Mice weight analysis of CDX model treated with anti-MSLN CART cells.¹

Efficacy Test of Anti-Mesothelin CAR-T in PDX Model

Fig.7 In vivo anti-tumor efficacy of anti-MSLN CART cells in PDX model. B). The tumor size measurement of PDX model treated with anti-MSLN CART cells. C). Mice weight analysis of PDX model treated with anti-MSLN CART cells.¹

Toxicity Evaluation Anti-Mesothelin CAR-T

Unexpected toxicity responses are often presented in the CART development and therapy. Creative Biolabs is dedicated to providing toxicity evaluation services by various means, including on-target / off-tumor analysis, and neurologic toxicity analysis.

Fig.8 Treatment effect analysis of mice treated with anti-MSLN CART cells. Immunohistochemistry analysis of granzyme B in tumor sections.¹

Reference

1. Zhang, Qian, et al. "The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice." Molecular Therapy-Oncolytics 20 (2021): 556-568.